Opus Genetics, Inc. (IRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $384.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Opus Genetics, Inc. (IRD) Competitors
The companies most similar to Opus Genetics are Ocugen (OCGN), Neurogene (NGNE) and Rocket Pharmaceuticals (RCKT). By market cap, Opus Genetics ranks 8th of the 13 companies on this page; Oric Pharmaceuticals (ORIC) is the largest at $814.71M.
Peer Comparison
IRD's ROIC of -145.1% is below the peer median of -15.4%, and its revenue growth of -63.1% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Opus Genetics (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Ocugen Inc (OCGN) | $280.88M | N/A | 54.9x | 0.0% | 271.0% | 11.4% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oculis Holding AG Ordinary shares (OCS) | $425.67M | N/A | N/A | 0.0% | N/A | -97.1% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Rezolute Inc (RZLT) | $353.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Peer median | $424.02M | N/A | 5.6x | 0.0% | -15.4% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Opus Genetics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ocugen Inc (OCGN) | Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. | OCGN competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Oculis Holding AG Ordinary shares (OCS) | Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. | OCS competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| Rezolute Inc (RZLT) | Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. | RZLT competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
Frequently Asked Questions About IRD
Who are Opus Genetics' main competitors?
The companies most similar to Opus Genetics include Ocugen (OCGN), Neurogene (NGNE), Rocket Pharmaceuticals (RCKT), Ovid Therapeutics (OVID) and Gyre Therapeutics (GYRE), listed from the closest match.
Who is Opus Genetics' biggest competitor?
Oric Pharmaceuticals (ORIC) is the largest of the similar companies at $814.71M; Ocugen (OCGN) is the closest match by business profile, size, sector and industry.
How does IRD stock compare with its competitors?
IRD's P/S is 52.0x against a peer median of 5.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Opus Genetics' competitors pays a higher dividend?
Opus Genetics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Opus Genetics bigger than its competitors?
No. Opus Genetics is 8th by market cap among the 13 companies on this page; the largest is Oric Pharmaceuticals (ORIC) at $814.71M.
IRD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors